Cargando…
Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations
INTRODUCTION: Humoral immunity after SARS-CoV-2 vaccination has been extensively investigated in blood. Aim of this study was to develop an ELISA method in order to determine the prevalence of IgG and IgA SARS-CoV-2 domain 1 spike-protein (S) specific antibodies (Abs) in buccal and nasal mucosal sur...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712976/ https://www.ncbi.nlm.nih.gov/pubmed/36466833 http://dx.doi.org/10.3389/fimmu.2022.999693 |
_version_ | 1784841905618550784 |
---|---|
author | Tsamadou, Chrysanthi Ludwig, Carolin Scholz, Judith Proffen, Matthias Hägele, Janina Rode, Immanuel Körper, Sixten Fabricius, Dorit Jahrsdörfer, Bernd Neuchel, Christine Amann, Elisa Schrezenmeier, Hubert Fürst, Daniel |
author_facet | Tsamadou, Chrysanthi Ludwig, Carolin Scholz, Judith Proffen, Matthias Hägele, Janina Rode, Immanuel Körper, Sixten Fabricius, Dorit Jahrsdörfer, Bernd Neuchel, Christine Amann, Elisa Schrezenmeier, Hubert Fürst, Daniel |
author_sort | Tsamadou, Chrysanthi |
collection | PubMed |
description | INTRODUCTION: Humoral immunity after SARS-CoV-2 vaccination has been extensively investigated in blood. Aim of this study was to develop an ELISA method in order to determine the prevalence of IgG and IgA SARS-CoV-2 domain 1 spike-protein (S) specific antibodies (Abs) in buccal and nasal mucosal surfaces of vaccinees. METHODS: To this end, we analyzed 69 individuals who received their first vaccine dose between February and July 2021. Vaccines administered were BNT162b2, mRNA-1273 or ChAdOx1-nCoV-19. Detection of IgG and IgA Abs was performed using commercial ELISA kits for both blood and swab samples after protocol modification for the latter. RESULTS: Anti-spike IgG and IgA Abs in the buccal and/or nasal swabs were detectable in >81% of the study subjects after the second dose. The IgG measurements in buccal swabs appeared to correlate in a more consistent way with the respective measurements in blood with a correlation coefficient of r=0.74. It is of note that IgA Abs appeared to be significantly more prevalent in the nasal compared to the buccal mucosa. Optimal selection of the assay cut-off for the IgG antibody detection in buccal swabs conferred a sensitivity of 91.8% and a specificity of 100%. Last, individuals vaccinated with mRNA-based vaccines exhibited higher antibody levels in both blood and mucosal surfaces compared to those receiving ChAdOx1-nCoV-19 confirming previously reported results. CONCLUSION: In conclusion, our findings show a differential prevalence of anti-S Abs on mucosal surfaces after vaccination for SARS-CoV-2, while they also set the basis for potential future use of IgG antibody detection in buccal swabs for extended immunity screening in large populations. |
format | Online Article Text |
id | pubmed-9712976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97129762022-12-02 Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations Tsamadou, Chrysanthi Ludwig, Carolin Scholz, Judith Proffen, Matthias Hägele, Janina Rode, Immanuel Körper, Sixten Fabricius, Dorit Jahrsdörfer, Bernd Neuchel, Christine Amann, Elisa Schrezenmeier, Hubert Fürst, Daniel Front Immunol Immunology INTRODUCTION: Humoral immunity after SARS-CoV-2 vaccination has been extensively investigated in blood. Aim of this study was to develop an ELISA method in order to determine the prevalence of IgG and IgA SARS-CoV-2 domain 1 spike-protein (S) specific antibodies (Abs) in buccal and nasal mucosal surfaces of vaccinees. METHODS: To this end, we analyzed 69 individuals who received their first vaccine dose between February and July 2021. Vaccines administered were BNT162b2, mRNA-1273 or ChAdOx1-nCoV-19. Detection of IgG and IgA Abs was performed using commercial ELISA kits for both blood and swab samples after protocol modification for the latter. RESULTS: Anti-spike IgG and IgA Abs in the buccal and/or nasal swabs were detectable in >81% of the study subjects after the second dose. The IgG measurements in buccal swabs appeared to correlate in a more consistent way with the respective measurements in blood with a correlation coefficient of r=0.74. It is of note that IgA Abs appeared to be significantly more prevalent in the nasal compared to the buccal mucosa. Optimal selection of the assay cut-off for the IgG antibody detection in buccal swabs conferred a sensitivity of 91.8% and a specificity of 100%. Last, individuals vaccinated with mRNA-based vaccines exhibited higher antibody levels in both blood and mucosal surfaces compared to those receiving ChAdOx1-nCoV-19 confirming previously reported results. CONCLUSION: In conclusion, our findings show a differential prevalence of anti-S Abs on mucosal surfaces after vaccination for SARS-CoV-2, while they also set the basis for potential future use of IgG antibody detection in buccal swabs for extended immunity screening in large populations. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9712976/ /pubmed/36466833 http://dx.doi.org/10.3389/fimmu.2022.999693 Text en Copyright © 2022 Tsamadou, Ludwig, Scholz, Proffen, Hägele, Rode, Körper, Fabricius, Jahrsdörfer, Neuchel, Amann, Schrezenmeier and Fürst https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tsamadou, Chrysanthi Ludwig, Carolin Scholz, Judith Proffen, Matthias Hägele, Janina Rode, Immanuel Körper, Sixten Fabricius, Dorit Jahrsdörfer, Bernd Neuchel, Christine Amann, Elisa Schrezenmeier, Hubert Fürst, Daniel Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations |
title | Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations |
title_full | Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations |
title_fullStr | Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations |
title_full_unstemmed | Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations |
title_short | Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations |
title_sort | differentially induced immunity in buccal and nasal mucosae after vaccination for sars–cov–2: prospects for mass scale immunity-screening in large populations |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712976/ https://www.ncbi.nlm.nih.gov/pubmed/36466833 http://dx.doi.org/10.3389/fimmu.2022.999693 |
work_keys_str_mv | AT tsamadouchrysanthi differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT ludwigcarolin differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT scholzjudith differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT proffenmatthias differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT hagelejanina differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT rodeimmanuel differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT korpersixten differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT fabriciusdorit differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT jahrsdorferbernd differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT neuchelchristine differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT amannelisa differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT schrezenmeierhubert differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations AT furstdaniel differentiallyinducedimmunityinbuccalandnasalmucosaeaftervaccinationforsarscov2prospectsformassscaleimmunityscreeninginlargepopulations |